Anfield Capital Management, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Anfield Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	SELL	$12.25 - $19.5 $23,520 - $37,440	-1,920 Reduced 47.08%	2,158 $40,000
Q3 2022 Nov 09, 2022	BUY	$7.06 - $15.52 $670 - $1,474	95 Added 2.39%	4,078 $52,000
Q2 2022 Aug 09, 2022	BUY	$6.23 - $8.57 $2,367 - $3,256	380 Added 10.55%	3,983 $28,000
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $10,673 - $16,703	2,010 Added 126.18%	3,603 $30,000
Q4 2021 Feb 03, 2022	BUY	$5.21 - $7.45 $7,648 - $10,936	1,468 Added 1174.4%	1,593 $11,000
Q3 2021 Nov 04, 2021	BUY	$4.85 - $6.04 $606 - $755	125 New	125 $1,000

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Anfield Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Anfield Capital Management, LLC with notifications on news.